EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical management of CMML —State of the art

K Nachtkamp iD, F Schulz, N Gattermann, U Germing

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2025. Verfasst von K Nachtkamp und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myelomonocytic leukaemias (CMML) are myeloid neoplasms characterized by a sustained increase in monocyte counts in the peripheral blood, accompanied by dysplasia, abnormal proliferation, chromosomal anomalies and somatic mutations of haematopoietic cells. More than 95% of CMML patients harbour somatic mutations. CMML must be separated from other myeloid neoplasms and reactive monocytosis. The clinical presentation of CMML varies, but most frequently shows signs and symptoms of haematopoietic insufficiency or myeloproliferation. Robust instruments are available for assessing the prognosis of patients with CMML, such as the CMML‐specific prognostic scoring system molecular. Treatment options for patients with CMML are still inadequate and generally less effective than those for other myeloid neoplasms. The only curative approach is allogeneic stem cell transplantation. This article explains essential aspects of CMML pathophysiology and provides an overview of diagnostic considerations, prognostic assessment and therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicHumansPrognosisHematopoietic Stem Cell TransplantationDisease ManagementMutation

Stichwörter der Autor:innen

CPSSmolMDS/MPN overlapchronic myelomonocytic leukaemiatreatment of CMML

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, Düsseldorf, Germany.

ORCID-Profile: K Nachtkamp

Zitieren

APA

Nachtkamp, K., Schulz, F., Gattermann, N., & Germing, U. (2025). Clinical management of CMML —State of the art. British Journal of Haematology. https://doi.org/10.1111/bjh.20213

Vancouver

Nachtkamp K, Schulz F, Gattermann N, Germing U. Clinical management of CMML —State of the art. British Journal of Haematology. 2025. doi:10.1111/bjh.20213

BibTeX
@article{Nachtkamp2025,
  author = {Nachtkamp, K and Schulz, F and Gattermann, N and Germing, U},
  title = {Clinical management of CMML —State of the art},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20213}
}
Kostenlos starten →